Boothbay Fund Management LLC Takes $3.81 Million Position in C.R. Bard, Inc. (BCR)

Boothbay Fund Management LLC bought a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,900 shares of the medical instruments supplier’s stock, valued at approximately $3,814,000.

Other hedge funds have also made changes to their positions in the company. Monroe Bank & Trust MI raised its stake in shares of C.R. Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 190 shares during the period. Parallel Advisors LLC increased its stake in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 14 shares during the period. Captrust Financial Advisors purchased a new position in C.R. Bard in the 2nd quarter worth about $192,000. Finally, Choate Investment Advisors purchased a new position in C.R. Bard in the 2nd quarter worth about $201,000. 79.11% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on BCR. Cowen reissued a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. ValuEngine cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Barclays lifted their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $305.00.

In related news, VP Betty D. Larson sold 5,906 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the sale, the vice president now directly owns 10,753 shares in the company, valued at $3,550,210.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $333.48, for a total transaction of $4,704,402.36. The disclosure for this sale can be found here. Insiders have sold 193,887 shares of company stock worth $63,801,024 over the last quarter. Insiders own 0.80% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE:BCR) traded down $1.95 during mid-day trading on Friday, hitting $331.24. 4,655,665 shares of the stock traded hands, compared to its average volume of 842,406. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. The firm has a market cap of $24,144.87, a PE ratio of 43.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. C.R. Bard, Inc. has a 1 year low of $222.42 and a 1 year high of $337.73.

C.R. Bard (NYSE:BCR) last posted its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. C.R. Bard’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.64 earnings per share. analysts expect that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were paid a dividend of $0.26 per share. The ex-dividend date was Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is presently 10.28%.

TRADEMARK VIOLATION WARNING: “Boothbay Fund Management LLC Takes $3.81 Million Position in C.R. Bard, Inc. (BCR)” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2017/12/30/boothbay-fund-management-llc-takes-position-in-c-r-bard-inc-bcr.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply